IRF1 expression might be a biomarker of CD8+ T cell infiltration in cutaneous melanoma

References

• Bertolotto C. Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo). 2013;2013:635203.
   PubMedGoogle Scholar
• Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463–482.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
   PubMed Web of Science ®Google Scholar
• van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–232.
   PubMed Web of Science ®Google Scholar
• Edwards J, Wilmott JS, Madore J, et al. CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment. Clin Cancer Res. 2018;24(13):3036–3045.
   PubMed Web of Science ®Google Scholar
• Thomas NE, Busam KJ, From L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013;31(33):4252–4259.
   PubMed Web of Science ®Google Scholar
• Jerby-Arnon L, Shah P, Cuoco MS, et al., A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175(4):984–997 e924.
   PubMed Web of Science ®Google Scholar
• Abbas O, Miller DD, Bhawan J. Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. Am J Dermatopathol. 2014;36(5):363–379.
   PubMed Web of Science ®Google Scholar
• Jefferies CA. Regulating IRFs in IFN driven disease. Front Immunol. 2019;10:325.
   PubMed Web of Science ®Google Scholar
• Shao L, Hou W, Scharping NE, et al. IRF1 inhibits antitumor immunity through the upregulation of PD-L1 in the tumor cell. Cancer Immunol Res. 2019;7(8):1258–1266.
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Takahashi A, Kikuchi R, et al. SOX10 regulates melanoma immunogenicity through an IRF4-IRF1 axis. Cancer Res. 2021;81(24):6131–6141.
   PubMed Web of Science ®Google Scholar
• Zhang L, Tsung A. Chapter 8 - role of the transcription factor interferon regulatory factor-1 in regulating autophagy in lipopolysaccharide-stimulated macrophages. In: Hayat MA, editor. Autophagy: cancer, other pathologies, inflammation, immunity, infection, and aging. Academic Press; 2017. p. 211–230.
   Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678.
   PubMed Web of Science ®Google Scholar
• Akbani R, Akdemir K, Aksoy B; Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–1696.
   PubMed Web of Science ®Google Scholar
• Karlsson M, Zhang C, Mear L, et al. A single-cell type transcriptomics map of human tissues. Sci Adv. 2021;7(31). DOI:10.1126/sciadv.abh2169.
   Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al., TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352):eaan2507.
   PubMed Web of Science ®Google Scholar
• Sonawane AR, Platig J, Fagny M, et al. Understanding tissue-specific gene regulation. Cell Rep. 2017;21(4):1077–1088.
   PubMed Web of Science ®Google Scholar
• Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics. 2017;33(18):2938–2940.
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116.
   PubMed Web of Science ®Google Scholar
• Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med. 2018;7(9):4509–4516.
   PubMed Web of Science ®Google Scholar
• Benci JL, Johnson LR, Choa R, et al. Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell. 2019;178(4):933–948 e914.
   PubMed Web of Science ®Google Scholar
• Grasso CS, Tsoi J, Onyshchenko M, et al. Conserved interferon-gamma signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell. 2021;39(1):122.
   PubMed Web of Science ®Google Scholar
• Lewinsky H, Gunes EG, David K, et al. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma. JCI Insight. 2021;6(4):e141683.
   PubMed Web of Science ®Google Scholar
• Rebmann V, Wagner S, Grosse-Wilde H. HLA-G expression in malignant melanoma. Semin Cancer Biol. 2007;17(6):422–429.
   PubMed Web of Science ®Google Scholar
• Cerezo M, Guemiri R, Druillennec S, et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 2018;24(12):1877–1886.
   PubMed Web of Science ®Google Scholar
• Cha JH, Chan LC, Li CW, et al. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359–370.
   PubMed Web of Science ®Google Scholar
• Kluger HM, Zito CR, Barr ML, et al. Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res. 2015;21(13):3052–3060.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Brien JD, Daffis S, Lazear HM, et al. Interferon regulatory factor-1 (IRF-1) shapes both innate and CD8(+) T cell immune responses against West Nile virus infection. PLoS Pathog. 2011;7(9):e1002230.
   PubMed Web of Science ®Google Scholar
• Huang Z, Zak J, Pratumchai I, et al. IL-27 promotes the expansion of self-renewing CD8(+) T cells in persistent viral infection. J Exp Med. 2019;216(8):1791–1808.
   PubMed Web of Science ®Google Scholar
• Ghislat G, Cheema AS, Baudoin E, et al. NF-kappaB-dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity. Sci Immunol. 2021; 6(61). DOI:10.1126/sciimmunol.abg3570
   PubMed Web of Science ®Google Scholar
• Emran AA, Chatterjee A, Rodger EJ, et al. Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol. 2019;40(4):328–344.
   PubMed Web of Science ®Google Scholar
• Jung H, Kim HS, Kim JY, et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun. 2019;10(1):4278.
   PubMedGoogle Scholar
• Murtas D, Maric D, De Giorgi V, et al. IRF-1 responsiveness to IFN-gamma predicts different cancer immune phenotypes. Br J Cancer. 2013;109(1):76–82.
   PubMed Web of Science ®Google Scholar